Scancell Holdings PLC SCLP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 10.10
- Day Range
- GBX 9.70–10.50
- 52-Week Range
- GBX 7.59–18.29
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 9.38 Bil
- Volume/Avg
- 211,828 / 396,869
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.scancell.co.uk
Comparables
Valuation
|
Metric
|
SCLP
|
FUSN
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 7.55 | 3.00 |
Price/Sales | — | 770.91 | 323.22 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SCLP
|
FUSN
|
CLDX
|
|---|---|---|---|
Quick Ratio | 8.63 | 10.37 | 31.44 |
Current Ratio | 8.63 | 10.64 | 31.77 |
Interest Coverage | −9.80 | −18.82 | — |
Quick Ratio
SCLP
FUSN
CLDX
Profitability
|
Metric
|
SCLP
|
FUSN
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −47.88% | −33.14% | −23.59% |
Return on Equity (Normalized) | — | −43.87% | −25.21% |
Return on Invested Capital (Normalized) | −83.96% | −36.42% | −25.04% |
Return on Assets
SCLP
FUSN
CLDX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ctvmfrkvd | Sbfw | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cvsthkkn | Rqrks | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bfvbtkh | Cdvhs | $106.7 Bil | |
MRNA
| Moderna Inc | Mkgrmcpvr | Zxtcm | $50.9 Bil | |
ARGX
| argenx SE ADR | Zfwsfcjlb | Ywzv | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Trkvyfw | Jwm | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lchwcnn | Lzyhvxk | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Glcyhmfyv | Nwlbmr | $14.6 Bil | |
INCY
| Incyte Corp | Rgkxprch | Ypclc | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zfdzmynsb | Wtvmnt | $12.6 Bil |